Table 1 Type of DPP-4 inhibitors, cardiovascular outcomes reported and follow-up time periods

Gantz2017 [7]

Omarigliptin

Cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular related death, fatal and non-fatal MI, fata and non-fatal stroke, all-cause mortality, hospitalization for heart failure, hospitalization for heart failure or cardiovascular death

96 weeks

Green2015 [8]

Sitagliptin

Cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, all-cause mortality

152 weeks

Park2015 [9]

Unspecified DPP-4 inhibitors

All-cause mortality

124 weeks

Scirica2013 [10]

Saxagliptin

Cardiovascular death/non-fatal MI or non-fatal stroke, all-cause mortality, cardiovascular death, MI, stroke, hospitalization for unstable angina, hospitalization for heart failure, hospitalization for coronary revascularization

109 weeks

Shih2016 [11]

Unspecified DPP-4 inhibitors

All-cause mortality, MACEs, MI, stroke, heart failure

114 weeks

Wang2015 [12]

Sitagliptin

Cardiovascular death/non-fatal MI or non-fatal stroke, MI, stroke, cardiovascular mortality

52 weeks

White2013 [13]

Alogliptin

Cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular mortality, non-fatal MI, non-fatal stroke, all-cause mortality

78 weeks